Neoprobe Expands Access to UCSD Developed Technology
|
 |
Monday, 12 May 08 - 03:08 PM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
"DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that Neoprobe and the University of California, San Diego (UCSD) have executed a definitive license agreement involving development rights to a molecular compound developed by researchers at UCSD. The new agreement accords Neoprobe the right to develop products using the compound for human medical applications incorporating optical or ultrasound technology. In addition, the development rights to the compound have been expanded to include veterinary applications. The compound is covered by U.S. patent 6,409,990 and corresponding issued patents in the European Union and Japan.
"William Decker, Assistant Director of the Office of Technology Transfer and Intellectual Property Services of UCSD, said, "We're pleased that our office could assist in working with Neoprobe to bring an additional use of this technology to the public at-large." [BusinessWire] MORE
UCSB takes role in diabetes drug project
|
|
|
Monday, 12 May 08 - 02:19 PM (GMT -08:00) By Bob Nidever in NEWS_Research |
| ||
" UC Santa Barbara has joined with drugmaker Pfizer and several institutions to foster research that could lead to better understanding and treatment of diabetes.
"Pfizer is putting up $14 million for the first three years of the project, one of the first of its kind. The project embraces a new approach to research that marks a shift in how university and pharmaceutical researchers work and serves as a model for the future, according to those involved in its creation.
'"We have a program at UCSB that is working very much at the interface of medicine and technology," said Frank Doyle, who is heading the project at the university. "Even in the absence of a medical school, we're able to work on partnerships with Big Pharma that are going to deliver enabling medical technology." [VenturaCountyStar]MORE
Startup Commercializes UCLA Technology for Wearable Artificial Kidney
|
|
|
Friday, 11 April 08 - 12:25 PM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
" Singapore – March 8, 2008: University of California, Los Angeles (UCLA) has entered into a world-wide, exclusive licensing agreement with AWAK Technologies Pte Ltd for the development and commercialization of a peritoneal-based automated wearable artificial kidney (AWAK) for the treatment of patients with end-stage renal disease (ESRD).
The peritoneal-based AWAK requires no extracorporeal circulation, and is therefore “bloodless”. It is designed to continuously regenerate and reuse the spent peritoneal dialysate in perpetuity and is, therefore, also “waterless”. A sorbent-based assembly regenerates both the aqueous and the protein components (AqC and PrC) of the spent peritoneal dialysate, and produces a novel, autologous protein-containing peritoneal dialysate. [BioSpace] MORE
An important feature of AWAK is that it is peritoneal dialysis-based. Current work by others on wearable artificial kidneys evolve around the technology of hemodialysis or hemofiltration, which require continuous anticoagulation of the extracorporeal circulation and are encumbered with potential immunologic and non-immunologic complications of continuous blood-artificial membrane interactions. Continuous extracorporeal circulation also exposes patients to the constant risk of exsanguinations through accidental disruption of the blood circuit. Prior clinically evaluated hemofiltration-based wearable artificial kidneys have consistently failed because of clotting within a week, in spite of aggressive anticoagulation.
Industry, UCSB ties are growing
|
|
|
Monday, 24 March 08 - 04:35 PM (GMT -08:00) By Bob Nidever in NEWS_Research |
| ||
Ideas from the university reach the market in a variety of ways. Professors at the university have started companies based on their research, and students have created their own companies while in the Technology Management Program.
There has been more than $650 million in venture funding in the past three years for companies with ties to UCSB.
There also are companies that do research at the university or invite university faculty and students into their labs. That's one reason for the corporate affiliates program — to create those partnerships." [VenturaCountyStar] MORE
UCI Startup, Neuromed, Tests Electronic Treatment for Pain, Depression
|
|
|
Thursday, 06 March 08 - 11:21 AM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
"'It sounded too good to be true," said Dave Schetter, the UCI administrator who oversees the university's dealings with technology companies.
" Hand-held electrical devices that zap away cold sores and genital herpes outbreaks, attacking them through the body's nervous system?
" Similar technology to combat pain, depression, tremors, Parkinson's disease and Alzheimer's disease?
" Schetter was nervous when he heard about the potential benefits of those devices, invented by Dr. Leon Silverstone and being prepared for regulatory approval and commercial launch by his company, NeuroMed Devices Inc. of Laguna Niguel. [ocregister] MORE
UCSD Startup, Traversa, Raises $2 Million in Angel-led Series A Financing
|
|
|
Monday, 03 March 08 - 08:13 AM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
" Traversa Therapeutics, Inc., a privately held developer of RNAi delivery technologies, announced recently the completion of a $2 million Series A financing led by the San Diego Tech Coast Angels and joined by investors Mesa Verde Venture Partners and Morningside Group.
" Traversa was founded with technology developed by Professor Steven F. Dowdy, Ph.D., and his research group at the Howard Hughes Medical Institute and the University of California San Diego (UCSD) relating to siRNA delivery and the induction of RNA Interference (RNAi). [venturecapital reporter] MORE
Cavity-fighting Herbal Lollipop Created by UCLA Professor, Developed by Startup
|
|
|
Thursday, 28 February 08 - 02:49 PM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
" UCLA microbiologist Wenyuan Shi collaborated with the research company C3 Jian to develop a therapeutic orange-flavored lollipop that is actually good for your teeth. Herbal treatments have been used in China for more than 3,000 years. Professor Shi studied and tested over 1,000 Chinese herbs and determined that an extract of licorice root (Glycyrrhiza uralensis) targets and kills the primary bacteria (streptococccus mutans or S.mutans) responsible for tooth decay. The sugar-free lollipop, marketed as Dr. John's Herbal Candy, is infused with a natural ingredient found in licorice that works against tooth decay. It appears that taking care of your teeth can actually be fun and tasty. [TheFutureofThings] MORE
UCSD project is lauded for startup help
|
|
|
Thursday, 28 February 08 - 02:34 PM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
" The William J. von Liebig Center at the University of California San Diego is a model in how to promote the commercialization of discoveries made in the university's classrooms and laboratories, according to a national study released yesterday.
" In its first six years, the center, at UCSD's Jacobs School of Engineering, fostered the startup of 16 companies that have acquired more than $71 million in private capital. The center also funded projects that resulted in four revenue-generating licenses for the university, according to the study by the entrepreneurship-boosting Ewing Marion Kauffman Foundation and the Max Planck Institute of Econmics. [SignOnSanDiego]MORE
UCSB gets serious about spin-offs
|
|
|
Monday, 25 February 08 - 07:15 AM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
" A new program to accelerate and streamline the creation of spin-off businesses from the world-class research at UC Santa Barbara has been launched. UCSB’s Venture Acceleration Initiative (VAI) program supports new ventures through a highly integrated approach to the complex process of moving technology from the lab bench to commercialization. The initiative will benefit not only faculty entrepreneurs and their investors, but will also provide a significant boost to the local and regional economies as the nascent businesses take shape and grow.
" Dr. Don Oparah, the founding director of VAI, emphasized the importance of partnership to the success of the new initiative, stating, “Working closely with the external business world, the local community and other key stakeholders across the state and beyond is an essential part of our strategy for delivering on the vision and promise of VAI.” [MercuryNews] MORE
New UCI Orange Coast Medical Ventures Incubator Already Helping Companies
|
|
|
Saturday, 23 February 08 - 08:14 PM (GMT -08:00) By Bob Nidever in NEWS_Incubators |
| ||
" Seventeen months ago, the idea of UCI-encouraged business incubators was hatched during a National Academy of Sciences workshop on making Orange County more competitive.
"The first one is focused on medical devices because Orange County is "an internationally recognized center for medical devices," in the words of David Schetter, UCI's assistant vice chancellor, who is spearheading creation of the innovation-boosting incubators.
"Four months ago, Orange Coast Medical Ventures was incorporated, the first of several projects envisioned as part of an Orange County Business Incubation Network.
"Now, the medical-device incubator has signed up five biomedical companies developing products they plan to sell to consumers, physicians, laboratories and fire departments. Several other companies are close to signing up, says Greg Ruehle, chief executive of the incubator. [ocregister] MORE
UCSB Faculty Startup Brings Locationing to Passive RFID
|
|
|
Saturday, 23 February 08 - 08:05 PM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
" A startup called Wirama has announced proprietary technology that it claims allows precise locationing using Gen2 passive RFID. It is an unusual application for passive RFID, which has historically been used to determine if a tagged object is present within a read field and what its tag data contains, but not to identify the exact position of the object. RFID Update spoke with Wirama co-founder and president Ben Wild about his company's innovation and its potential applications. [RFIDupdate] MORE
Startup licenses UCLA technology based on modified E.coli bacteria to make biofuel production more efficient
|
|
|
Thursday, 31 January 08 - 03:54 PM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
" Researchers at UCLA's Henry Samueli School of Engineering and Applied Science have found that by using a modified form of the E. coli bacteria, they can actually make biofuels more efficiently. Gevo, a Pasadena, Calif.-based biofuel startup that is licensing the technology through an exclusive royalty-bearing license, could benefit from the research. " [greentechmedia] MORE
UCLA-industry partnership to develop, commercialize new nanotechnology
|
|
|
Monday, 17 December 07 - 03:15 PM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
"We are looking forward to launching this collaboration and working in a seamless fashion with UCLA and the world-class scientific team at the CNSI to develop and commercialize nano technology," said Joseph A. Boystak, Chairman & Co-CEO of NanoPacific Holdings. "We intend to prioritize and aggressively pursue multiple applications in the medical, consumer, environmental and industrial sectors and in doing so we envision spawning a series of companies and partnerships with important commercial partners to accelerate the roll out of this technology."
"The breadth of commercial applications for technologies arising from university nanotechnology research is enormous and UCLA is excited to be working with the team of business and scientific talent at NanoPacific to bring nanotech-enabled products to market to benefit patients and society at large," said Earl Weinstein, PhD and Assistant Director of Technology Transfer at UCLA. "This startup is part of a growing number of high tech companies resulting from research at UCLA that have chosen to establish themselves locally, which also benefits the burgeoning Los Angeles tech cluster. We look forward to a long and productive relationship with them," Weinstein added. [ucla press release] MORE
UCLA Faculty Startup, Unidym, Inc., Closes $10.4 Million Round Led by Financial and Strategic Institutions
|
|
|
Thursday, 06 December 07 - 07:42 AM (GMT -08:00) By Bob Nidever in NEWS_Startups |
| ||
“We are excited to further strengthen our alliance with Battelle and begin our relationship with Tokyo Electron, one of the world’s largest electronics equipment suppliers,” said Art Swift, Unidym’s CEO. “We look forward to working with both partners in commercializing carbon nanotube based electrodes and transistors for the touch panel, display and solar industries.”
“We believe Unidym is well positioned to be a leader in the future era of flexible displays and printed electronics,” remarked Mike Yamaguchi, President of TEL Venture Capital, Inc. As a leading global supplier of semiconductor and flat panel display production equipment, Tokyo Electron Limited (TEL) engages in development, manufacturing, and sales in a wide range of product fields. [business wire]MORE
UCSD Technology Licensed by Memgen, Inc. in Clinical Trials for Chronic Lymphocytic Leukemia
|
|
|
Wednesday, 05 December 07 - 06:06 AM (GMT -08:00) By Bob Nidever in NEWS_Licensing |
| ||
Patients with chronic lymphocytic leukemia (CLL) who have failed chemotherapy or have chosen to forego chemotherapy have an opportunity to participate in a new clinical trial for a CLL vaccine being conducted at the Moores Cancer Center at the University of California, San Diego (UCSD).
Study participants will receive Memgen’s ISF35, an immune therapy product, or vaccine. Based on the results of previous studies, ISF35 has the potential to stimulate the immune system to act against CLL cells and fight them naturally. Memgen, a biomedical company headquartered in Dallas, Texas, licensed the technology for the ISF35 molecule from UCSD and continues clinical development of the molecule.
ISF35 is an abbreviation for Immune Stimulatory Factor 35, which is an offspring of technology discovered by Thomas J. Kipps, M.D., Ph.D., professor in the UCSD Department of Medicine and deputy director for research at the Moores Cancer Center.
“ISF35 gene therapy represents the next generation of leukemia-targeting vaccine strategies for patients with CLL,” said Kipps. “It is designed to activate dormant leukemia B-cells and rally T-cells to selectively attack blood- and tissue-based leukemia cells.” [ucsd press release]MORE
... More items are available in our News Archive
